Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Total Current Liabilities data on file, last reported at $231.6 million in Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $231.6 million, up 7.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $231.6 million (up 7.03% YoY), and the FY2025 annual result was $231.6 million, up 12.94% from the prior year.
• Total Current Liabilities climbed to $231.6 million in Q4 2025 per TLX's latest filing, from $216.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $231.6 million in Q4 2025 and troughed at $107.5 million in Q4 2023.
• A 3-year average of $185.2 million and a median of $216.4 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 101.39% in 2024, then climbed 7.03% in 2025.
• A 3-year view of Total Current Liabilities shows it stood at $107.5 million in 2023, then jumped by 101.39% to $216.4 million in 2024, then increased by 7.03% to $231.6 million in 2025.
• Business Quant data shows TLX's Total Current Liabilities at $231.6 million in Q4 2025, $216.4 million in Q4 2024, and $107.5 million in Q4 2023.